Board of Directors

Philippe Amouyal, Director
Managing Director of Invus LP​

Philippe joined Invus in 1999 as a Managing Director, based in Boston. Prior to joining Invus, Philippe spent 15 years at The Boston Consulting Group in Paris and Boston, where he was a Vice President and Director and coordinated the global electronics and software practice from 1991 on. He holds an MS in engineering and a DEA in management from Ecole Centrale de Paris and was a Research Fellow at the Center for Policy Alternatives of the Massachusetts Institute of Technology. Philippe currently serves as a director for Weight Watchers International (NYSE: WTW), Lexicon Pharmaceuticals (NASDAQ:LXRX), and previously was a director at Unwired Group (ASX: UNW).

Jamie Heywood, Chairman
Co-Founder and Chairman, PatientsLikeMe​

An MIT-trained mechanical engineer, Jamie entered the field of translational medicine when his 29 year old brother Stephen was diagnosed with ALS, or Lou Gehrig's Disease. Jamie co-founded PatientsLikeMe to ensure patient outcomes become the primary driver of the medical care and discovery process. Jamie is also the founder and past CEO of the ALS Therapy Development Institute (ALS TDI), the world's first non-profit biotechnology company. During his tenure at ALS TDI, Jamie helped pioneer an open research model and industrialized therapeutic validation process that made ALS TDI the world's largest and most comprehensive ALS research program. Jamie has founded or co-founded three other health care companies: AOBiome, Genetic Networks, and Love Steve, and is an active member of a community of innovators working to bring dramatic improvements to the way we discover, develop and deliver effective health. Jamie and his brother were the subject of Pulitzer Prize-winning author Jonathan Weiner's biography His Brother’s Keeper, and the documentary So Much So Fast.

Jun Wang, Director
Founder and CEO of iCarbonX​

Dr. Wang co-founded Beijing Genomics Institute (BGI) in 1999, which is now widely recognized as one of world’s premier research facilities committed to excellence in genome sciences. During this time, Dr. Wang managed three rounds of fundraising (about 1B$ in total), and acquired a U.S. public company, Complete Genomics. He was recognized with numerous awards and nominations, such as His Royal Highness Prince Foundation, and “Fortune’s 40 under 40” by Fortune Magazine (2013) and “Highly Cited Researchers 2015” by Thomson Reuters. Dr. Wang founded iCarbonX in 2015. He holds a bachelor’s degree in artificial intelligence and a Ph.D. in bioinformatics from Peking University.

Cindy Yang, Director
Partner and Chief Investment Officer of iCarbonX​

Ms. Yang is the founder of Athenee Capital and is a Venture Partner at Qiming Ventures, a $3 billion USD venture capital fund. Ms. Yang has led and participated in landmark investment deals for a range of mobile, financial technology, social commerce, education and entertainment companies, including Xiaomi, Wacai, Mogujie, VIP abc and Hairun. Before that she spent a decade with Microsoft Corporation in the United States and China, managing technology and business development departments and the Asia Strategic Fund with government and research institutions. Ms. Yang holds advanced degrees from Peking University and the University of Washington.